胰岛素受体、p53在合并2型糖尿病乳腺癌患者肿瘤组织中的表达及临床研究

目的探讨胰岛素受体、p53肿瘤分子学指标在合并2型糖尿病乳腺癌患者肿瘤组织中的表达情况,并对其与2型糖尿病的关系及临床价值做出评判。方法合并2型糖尿病乳腺癌患者68例,对照非糖尿病乳腺癌组患者145例,取石蜡切片作胰岛素受体,p53指标的免疫组化检测。并分析比较两组指标的阳性率。结果在合并2型糖尿病组中,胰岛素受体阳性比例76.5%(52/68),阴性23.5%(16/68),对照组胰岛素受体阳性比例31.7%(46/145),阴性68.3%(99/145),二者在统计学上有差别(χ2=37.3,P<0.01)。在合并2型糖尿病组中,p53阳性比例66.2%(45/68),阴性33.8%(23/68),对照组p53阳性比例47.6%(69/145),阴性52.4%(76/145),二者在统计学上有差别(χ2=6.43,P<0.05)。结论在2型糖尿病合并乳腺癌患者肿瘤组织中胰岛素受体高表达,p53突变,预示患者不良预后,因加强随访及治疗。

Expression and Clinical Study of IR and p53 in Tumor Tissue of Breast Cancer Patients with Type-2 Diabetes Mellitus

Objective To investigate the expression of IR（insulin receptor）and p53 in the tumor of breast cancer patients with type 2 diabetes mellitus. Methods 68 breast cancer patients with type 2 diabetes mellitus who underwent surgery were analyzed retropectively. The expression of IR and p53 measured by immunohistochemistry（IHC）were compared to the 145 patients without type 2 diabetes mellitus. Results There was a statistically significant difference of IR and p53 expression between the patients with type 2 diabetes mellitus and the non-ones. Conclusion There were more patients with IR and p53 positive in type 2 diabetes mellitus group, which might indicate the pathogenisis of breast cancer. However, if they exerted aprognostic effect on breast cancer patients need further study.